Total tau in cerebrospinal fluid differentiates Alzheimer's disease from vascular dementia

Medical Science Monitor

Volumn 9, Issue 11, 2003, Pages

  Leszek, Jerzy ^a   Małyszczak, Krzysztof ^a   Janicka, Barbara ^a   Kiejna, Andrzej ^a   Wiak, Andrzej ^b  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b MILITARY HOSPITAL   (Poland)

Author keywords

Neurofibrillary tangles; Neurondamage; Vascular dementia

Indexed keywords

TAU PROTEIN;

ADULT; AGE; AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MULTIINFARCT DEMENTIA; NEUROFIBRILLARY TANGLE; PROTEIN ANALYSIS; PROTEIN CEREBROSPINAL FLUID LEVEL;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; DEMENTIA, VASCULAR; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; NEURONS; TAU PROTEINS;

EID: 1642483648     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Buchet R, Pikula S: Alzheimer's disease: Its origin at the membrane, evidence and questions. Acta Biochim Pol, 2000; 47(3): 725-733
2. Small DH, McLean CA: Alzheimer's disease and the amyloid b protein: What is the role of amyloid? J Neurochem, 1999; 73: 443-449
3. Mandelkow EM, Mandelkow E: Tau in Alzheimer's disease. Cell Biol, 1998; 8: 425-427
4. Goedert M: Tau protein and neurofibrillary pathology of Alzheimer's disease. Trends Neurosci, 1993; 16: 460-465
5. Blennow K, Vanmechelen E, Hampel H: CSF total tau, Abeta 42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol Neurobiol, 2001; 1-3: 87-97
6. Hock C, Golombowski S, Naser W, Muller-Spahn F: Increased levels of Tau protein in cerebrospinal fluid of patients with Alzheimer's disease - correlation with degree of cognitive impairment. Ann Neurol, 1995; 37: 414-415
7. Galasko D: Biological markers and the treatment of Alzheimer's disease. J Mol Neurosci, 2001; 2: 119-125
8. Hu JJ, He SS, Wang XC, Duan QH, Khatoon S, Iqbal K, Grundke Iqbal J: Elevated levels of phoshorylated neurofilament proteins in cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett, 2002; 3: 156-160
9. Jenkins SM, Zinnermann M, Garner C, Johnson GVW: Modulation of tau phosphorylation and intracellular localization by cellular stress. Biochem J, 2000; 345: 263-270
10. Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov, 2003; 2(7): 566-580
11. Lau LF, Schachter JB, Seymour PA, Sanner MA: Tau protein phosphorylation as a therapeutic target in Alzheimer's disease. Curr Top Med Chem, 2002; 4: 395-415
12. Tanaka T, Wada K, Yamamori H, Tanaka S, Kudo T, Takeda M. [Biological markers for Alzheimer disease]. Seishin Shinkeigaku Zasshi, 2003; 105(4): 387-92 [Article in Japanese with English abstract]
13. Maddalena A, Papassotiropoulos A, Muller-Tillmanns B, Jung HH, Hegi T, Nitsch RM, Hock C. Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide 42. Arch Neurol, 2003; 60(9): 1202-1206
14. Andreasen N, Vanmechelen E, Van de Voorde A: Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. J Neurol Neurosurg Psychiatry, 1998; 64: 298-305
15. Galasko D. CSF tau and Abeta 42: logical biomarkers for Alzheimer's disease? Neurobiol Aging, 1998; 19: 117-119
16. Riemenschneider M, Kurz A, Bertram L, Lautenschloger V, Förstl H: Diagnosis of Alzheimer's disease using biological markers. Neurobiol Aging, 1998; 674: S160
17. Arai H, Terajima M, Miura M: Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer's disease. Ann Neurol, 1995; 38: 649-652
18. Pachalska M, Kurzbauer H, Grochmal-Bach B, MacQueen BD, Knapik H: Róźnie owanie neuropsychologiczne otȩpienia o typie Alzheimerowskim z otȩpieniem z ciałami Lewy' ego. Rocznik Psychogeriatryczny, 2002; 5: 23-35 [in Polish with English summary]
19. Gomez-Tortosa E, Gonzalo I, Fanjul S, Sainz MJ, Cantarero S, Cemillan C, Yebenes JG, del Ser T. Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease. Arch Neurol, 2003; 60(9): 1218-22
20. McKhan G, Drachman D, Folstein M: Clinical diagnosis of Alzheimer's disease: report of the NINCDS - ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology, 1984; 34: 939-944
21. Roman GC, Tatemichi TK, Erkinjuntti T: Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS - AIREN International Work Group. Neurology, 1993; 43: 250-260
22. Folstein MF, Folstein SE, McHough PR: Mini Mental State: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res, 1975; 12: 189-198
23. Vondermeeren M, Mercken M, Vanmechelen E: Detection of Tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme linked immunosorbent assay. J Neurochem, 1993; 61: 1828-1834
24. Hampel H, Buerger K, Kohnken R, Teipel SJ, Zinkowski R, Moeller HJ, Rapoport SI, Davies P: Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231. Ann Neurol, 2001; 49: 545-546
25. Hesse C, Rosengren L, Andreasen N, Davidsson P, Vanderstichele H, Vanmechelen E, Blennow K: Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett, 2001; 297: 187-190
26. Buerger K, Zinkowski R, Teipel SJ et al. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol, 2002; 59: 1267-1272
27. Kapaki E, Paraskevas GP, Zalonis I, Zournas C. CSF tau protein and beta amyloid (1-42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population. Eur J Neurol, 2003; 10(2): 119-28
28. Caputo CB, Sygowski LA, Scott CW, Sobel IRE: Role of Tau in the polymerization of peptides from β-amyloid precursor protein. Brain Res, 1992; 597: 227-232
29. King ME, Ahuja V, Binder LI, Kuret J: Ligand dependent tau filament formation: Implications for Alzheimer's disease progression. Biochemistry, 1999; 38: 14851-14859
30. Ingelson M, Blomberg M, Benedikz E, Wahlund L-O, Karlsson E, Vanmechelen E, Lannfelt L: Tau immunoreactivity detected in human plasma, but no obvious increase in dementia. Dement Geriatr Cogn Disord, 1999; 10: 442-445
31. Molina L, Touchon J, Herpe M et al.: Tau and apoE in CSF: potential aid for discriminating Alzheimer's disease from other dementias. NeuroReport, 1999; 10: 3491-3495